Menu

Pre-market: Higher opening seen; RIL, United Bank of India in focus

Glenmark Pharma up on plans to out-license molecule for pain management

The molecule, GRC 17536, is expected to have a market potential worth $ 1 billion.

Pre-market: Higher opening seen; RIL, United Bank of India in focus

Glenmark Pharma up on plans to out-license molecule for pain management

The molecule, GRC 17536, is expected to have a market potential worth $ 1 billion.

SgxNifty.org is for Stock Market Information purposes only and is not associated with SGX / NSE / NSEIX / IFSC / Gift City / Nifty

SgxNifty.org is not a Financial Adviser / Influencer and does not provide any trading or investment skills / tips / recommendations via its website / directly / social media or through any other channel.

Disclaimer / Disclosure and Privacy Policy / Terms and conditions are applicable to all users /members of this website.

The usage of this website means you agree to all of the above